---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-115453"
form_type: "8-K"
ticker: "VERU"
cik: "0000863894"
company_name: "VERU INC."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T06:13:11.745582+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Veru's enobosarm Phase 2b meets primary endpoint; 71% less lean mass loss with GLP-1

## Summary
- Phase 2b QUALITY study met primary endpoint: 71% relative reduction in lean mass loss with enobosarm + semaglutide vs placebo (p=0.002).
- Enobosarm 3mg dose resulted in >99% mean relative reduction in lean mass loss (p<0.001); enobosarm 6mg not more effective.
- Enobosarm + semaglutide shifted weight loss composition to fat: 90.6% fat loss vs 68% with placebo (p=0.014 for fat mass loss with 6mg).
- Physical function improved: 54.4% relative reduction in proportion with ≥10% decline in stair climb power (p=0.0049) for all enobosarm.
- Upcoming catalysts: unblinded safety data and Phase 2b extension topline data expected in Q2 2025; End of Phase 2 FDA meeting planned for Q3 2025.

## SEC filing metadata
- accession: 0001193125-25-115453
- form_type: 8-K
- ticker: VERU
- cik: 0000863894
- company_name: VERU INC.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/863894/000119312525115453/0001193125-25-115453-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/863894/000119312525115453/d937042d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-115453
- JSON: https://secwatch.observer/filing/0001193125-25-115453.json
- Plain text: https://secwatch.observer/filing/0001193125-25-115453.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.